title: Sorafenib-induced bilateral osteonecrosis of femoral heads.
authors.affiliation: Hospices Civils de Lyon, Hôpital Edouard Herriot, Fédération des Spécialités Digestives, Lyon, France.
authors.forename: Marielle
authors.initials: M
authors.lastname: Guillet
authors.forename: Thomas
authors.initials: T
authors.lastname: Walter
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Thierry
authors.initials: T
authors.lastname: Vial
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
authors.forename: Jérôme
authors.initials: J
authors.lastname: Dumortier
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D005271:Femur Head Necrosis / Q000139:chemically induced*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib